Immune Checkpoint Inhibitors Market by Drug Type (Brand) – Atezolizumab (Tecentriq, MPDL3280A), Durvalumab (Imfinzi, MEDI4736), Ipilimumab (Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda) and Forecast 2017-2025

Immune Checkpoint Inhibitors Market by Drug Type (Brand) – Atezolizumab (Tecentriq, MPDL3280A), Durvalumab (Imfinzi, MEDI4736), Ipilimumab (Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda) and Forecast 2017-2025

Immune checkpoint Inhibitor drugs blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. There are two main immune checkpoint molecules, cytotoxic T‑lymphocyte protein 4 (CTLA4) and programmed cell-death protein 1 (PD1), that negatively regulates cytotoxic T‑cell activation. Three immune checkpoint inhibitors for the treatment of malignant melanoma and currently available in the market includes ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda). In 2011, US Food and Drug Administration (FDA) approved ipilimumab, monoclonal CTLA4-specific antibody, while pembrolizumab, a PD1-specific monoclonal antibody gained accelerated FDA approval for advanced and unresectable malignant melanoma in 2014, and nivolumab, an anti-PD1 and BRAF inhibitor was granted breakthrough therapy designation (BTD) status in 2015. A number of drug combinations that include checkpoint inhibitors are in clinical development. Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. The early success of immune checkpoint inhibitors in solid tumors and cancer immunotherapies in general has generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

The global immune checkpoint inhibitors market segmentation is based on drug type (brand) – atezolizumab (Tecentriq, MPDL3280A), durvalumab (Imfinzi, MEDI4736), ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda).

The global immune checkpoint inhibitors market research report provides market size (Revenue US$ Million 2014 to 2025), market share analysis, growth trends and forecast (CAGR%, 2017 to 2025). The global immune checkpoint inhibitors market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global immune checkpoint inhibitors market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global immune checkpoint inhibitors market and profiled in this report include AstraZeneca, Bristol-Myers Squibb, CureTech Ltd., Incyte, Medimmune, Merck & Co., NewLink Genetics, Ono Pharmaceuticals, Pfizer, and Roche (Genentech).

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Immune Checkpoint Inhibitors Market

1. Drug Type
1.1. Atezolizumab (Tecentriq, MPDL3280A)
1.2. Durvalumab (Imfinzi, MEDI4736)
1.3. Ipilimumab (Yervoy)
1.4. Nivolumab (Opdivo)
1.5. Pembrolizumab (Keytruda)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. AstraZeneca
3.2. Bristol-Myers Squibb
3.3. CureTech Ltd.
3.4. Incyte
3.5. Medimmune
3.6. Merck & Co.
3.7. NewLink Genetics
3.8. Ono Pharmaceuticals
3.9. Pfizer
3.10. Roche (Genentech)

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*